Recent advances in the pharmacotherapy of infantile spasms

CNS Drugs

Volumn 28, Issue 4, 2014, Pages 279-290

  Riikonen, Raili ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACHTAR; ANTICONVULSIVE AGENT; CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN ZINC; DEXAMETHASONE; ETIRACETAM; GANAXOLONE; GLUCOCORTICOID; HYDROCORTISONE; LAMOTRIGINE; METHYLPREDNISOLONE; NITRAZEPAM; PREDNISOLONE; PREDNISONE; PYRIDOXINE; RAPAMYCIN; S CORTROPHIN Z; SULTIAME; TETRACOSACTIDE; TETRACOSACTIDE ZINC PHOSPHATE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADRENAL INSUFFICIENCY; CRYPTOGENIC SPASM; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAM; EPILEPSY; HUMAN; HYPERTENSION; INCIDENCE; INFANTILE SPASM; INFECTION; IRRITABILITY; KETOGENIC DIET; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; TREATMENT DURATION; TUBEROUS SCLEROSIS; VISUAL FIELD DEFECT; ANIMAL; COGNITION DISORDERS; NEWBORN; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPASMS, INFANTILE;

ADRENAL CORTEX HORMONES; ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTICONVULSANTS; COGNITION DISORDERS; HUMANS; INFANT, NEWBORN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPASMS, INFANTILE; VIGABATRIN;

EID: 84899079559     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0139-5     Document Type: Review

References (118)

1. Benedek K, Juhasz C, Chugani D, et al. Longitudinal changes in cortical glucose hypometabolism in children with intractable epilepsy. J Child Neurol. 2006;21:26-31.
2. Berg A, Berkovic S, Brodie M, et al. Revised terminology and concepts for organization of seizures and epilepsies. Report of the ILEA Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51:676-85.
3. Riikonen R. Favourable prognostic factors with infantile spasms. Eur J Ped Neurol. 2010;14:13-8.
4. Osborne J, Lux A, Edwards S et al. The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom Infantile spasms Study (UKISS) on contemporary causes and their classification. Epilepsia 2010;51(10):2168-74
5. Yu J, Pearl P. Metabolic causes of epileptic encephalopathy. Epilepsy Res Treat. 2013;2013:124934. doi: 10.1155/2013/124934.
6. Dunin-Wasowitcz D, Kasprzyk-Obara J, Jurkiewicz E, et al. Infantile spasms and cytomegalovirus infection: antiviral and antiepileptic treatment. Dev Med Child Neurol. 2007;49:884-92.
7. Go C, Mackay M, Weiss S, et al. Evidence-based guide line update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78:1974-80.
8. Hancock E, Osborne J. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol. 1999;14:71-4.
9. Paciorkowski A, Thio L, Dobyns W. Genetic and biologic classification of infantile spasms. Pediatr Neurol. 2011;20:197-202.
10. Kivity S, Lerman P, Ariel B, et al. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia. 2004;45:255-62.
11. Granström M-L, Gaily E, Liukkonen E. Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms. Epilepsia. 1999;40:950-7.
12. Hancock E, Osborne J, Edwards S. Treatment of infantile spasms. Cochrane Database Syst Rev. 2013;(6):CD001770
13. Riikonen R. Epilepsy: update to guidelines on treatment of infantile spasms. Nat Rev Neurol. 2012;8(9):480-2
14. Sorel L, Dusaucy-Bayloye H. A propos de 21 cas d'hypsarythmie de Gibbs. Son Traitement spectaculaire par lÀCTH. Acta Neurol Belg. 1958;58:130-41.
15. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms. Report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62(10):1668-81.
16. Lux A, Osborne J. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi Group. Epilepsia. 2004;45:1416-28.
17. Treadwell B. Comparison of depot tetracosactrin and corticotrophin gel. BMJ. 1969;4:720-3.
18. Riikonen R. ACTH therapy of West syndrome: Finnish views. Brain Dev. 2001;23:642-6.
19. Gettig J, Cummings J, Matuszewski K. H.p. Acthar gel and cosyntropin review: clinical and financial implications. Pharm Ther. 2009;34(5):250-7.
20. Fukuyama Y. The Japanese scheme of ACTH therapy in West syndrome. Epilepsia. 2010;51:2216-8.
21. Riikonen R. A European perspective - comments on "Infantile spasms": a U.S. consensus report. Epilepsia. 2010;5:2215-6.
22. Lux A, Edwards S, Hancock E, et al. The United Kingdom infantile spasm study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomized controlled trial. Lancet. 2004;364:1773-8.
23. Pellock J, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia. 2010;51:2175-89. doi: 10.1111/j.1528-1167.2010. 02657.x.
24. Baram T, Michell W, Tourney A, et al. High-dose corticotrophin therapy for infantile spasms. Pediatrics. 1996;97:375-9.
25. Stafstrom C, Arnason B, Baram T, et al. Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol. 2011;26:1411-21.
26. Gaily E, Liukkonen E, Paetau R, et al. Infantile spasms: diagnosis and assessment of treatment response by video-EEG. Dev Med Child Neurol. 2001;43:658-67.
27. Hrachovy R, Frost J, Glaze D. High-dose, long-duration versus low-dose, short-duration corticotrophin therapy for infantile spasms. J Pediatr. 1994;124:803-6.
28. Yanagaki S, Oguni H, Hayashi K, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome. Brain Dev. 1999;21:461-7.
29. Riikonen R. A long-term follow-up study of 214 children with earlier infantile spasms. Dev Med Child Neurol. 1981;23:747-60.
30. Riikonen R. Long-term outcome of patients with West syndrome. Brain Dev. 2001;23:683-7.
31. Appleton R, Peters A, Mumford J, et al. Randomized, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia. 1999;40:1627-33.
32. Willmore L, Abelson M, Ben-Menachem E, et al. Vigabatrin: update 2008. Epilepsia. 2009;50:163-73.
33. Vigabatrin Pediatric Advisory Group. Guideline for prescribing vigabatrin in children has been revised. BMJ. 2000;320:1404.
34. Heiskala H, Riikonen R, Santavuori P, et al. West syndrome: individualized ACTH therapy. Brain Dev. 1996;18:456-60.
35. Partikian A, Michell W. Neurodevelopmental and epilepsy outcomes in North American cohort of patients with infantile spasms. J Child Neurol. 2010;25:423-8.
36. Sapolsky G. Glucocorticoids, stress and exitotoxic neuron death. Semin Neurosci. 1994;6:323-31.
37. Bittigau P, Sifringer R, Ikonomidu C. Antiepileptic drugs and apoptosis in the developing brain. Ann NY Acad Sci. 2003;993:103-14.
38. Turski C, Ikonomidou C. Neuropathological sequelae of developmental exposure to antiepileptic and anesthetic drugs. Front Neurol. 2012;3:120.
39. Vigevano P, Cilio M. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia. 1997;38:1270-4.
40. Elterman R, Shields W, Mansfield K, Nakagawa J, the US Infantile Spasms Vigabatrin Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57:1416-21.
41. Elterman RD, Shields WD, Bittman RM. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. Child Neurol. 2010;25:1340-7.
42. Cohen-Sadan S, Kramer U, Ben-Zeev B, et al. Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. Eur J Neurol. 2009;16(4):482-7.
43. Ibrahim S, Gulab S, Ishaque S, et al. Clinical profile and treatment of infantile spasms using vigabatrin and ACTH: a developing country perspective. BMC Pediatr. 2010;10:1
44. Mohamed B, Scott R, Desai N, et al. Seizure outcome in infantile spasms: a retrospective study. Epilepsia. 2011;52:746-52.
45. Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997;26:389-95.
46. Wohlrab G, Bolthauser E, Schmitt B. Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics. 1998;29:133-6.
47. Aicardi J, Mumford JP, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia. 1999;37:637-42.
48. Lombroso CT. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia. 1983;24:135-48.
49. Askalan R, Mavkay M, Brian J, et al. Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. J Child Neurol. 2003;18:165-70.
50. Lux A, Edwards S, Hancock E, et al. United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes at age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4:712-7.
51. Darke K, Edwards SW, Hancock E, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child. 2010;95:382-6.
52. Stewart P, Krone N. Therapeutic corticosteroids. Chapter 15 Adrenal cortex. In: Melmed S, Polonsky K, Larsen R, Kronenberg H, editors. Williams Textbook of Endocrinology, 12th edn. 2011.
53. Shulman D, Palmert M, Kemp S, et al. Adrenal insufficiency: still a cause of morbidity and death in childhood. Pediatrics. 2007;119:e484-94.
54. Axelrod L. Corticosteroid therapy. In: Becker K, editor. Principles and practice of endocrinology and metabolism. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 751-64.
55. Grossman A, Johannsson G, Quinker M, et al. Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol. 2013;169:R165-75.
56. Marik P, Zaloga G. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest. 2002;122:1784-96.
57. Perheentupa J, Riikonen R, Dunkel L, et al. Adrenocortical hyporesponsiveness after treatment with ACTH of infantile spasms. Arch Dis Child. 1986;6:750-3.
58. Azam M, Bhatti N, Krishin J. Use of ACTH and prednisolone in infantile spasms: experience from a developing company. Seizure. 2005;14(8):552-6.
59. Singhi P, Ray M. Profile of West syndrome in North Indian Children. Brain Dev. 2005;27:135-40.
60. Kossoff E, Hartman A, Rubenstein J, et al. High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH. Epilepsy Behav. 2009;14:674-6.
61. Mytinger JR, Quigg M, Taft W, et al. Outcomes in treatment of infantile spasms with pulse methylprednisolone. J Child Neurol. 2010;25:948-53.
62. Haberlandt E, Weger C, Baumgartner Sigl S, et al. Adrenocorticotropic hormone versus pulsatile dexamethasone in the treatment of infantile epilepsy syndromes. Pediatr Neurol. 2010;42:21-7.
63. Kerrigan J, Shields W, Nelson T, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 2000;42:133-9.
64. Rogawski M, Reddy D. Neurosteroids and infantile spasms: the deoxycorticosterone hypothesis. Int Rev Neurobiol. 2002;49:199-219.
65. Tsai J, Pellock JM, von Hehn J, et al. A double-blind, placebo-controlled, dose ranging clinical study to evaluate the safety, tolerability, and antiepileptic activity of ganaxolone in treatment of patients with infantile spasms. Neurology. 2009;72(11 Suppl 3):A119.
66. Riikonen R, Donner M. ACTH therapy of infantile spasms: side effects. Arch Dis Child Neurol. 1980;55:664-72.
67. Nousiainen I, Mäntyjärvi M, Kälviäinen R. No revision in vigabatrin-associated visual field defects. Neurology. 2001;57:1916-7.
68. Marguire M, Hemming K, Wild J, et al. Prevalence of visual field loss following to vigabatrin therapy: a systematic review. Epilepsia. 2010;51:2423-31.
69. Gaily E, Jonsson H, Lappi M. Visual field defects at school-age in children treated with vigabatrin in infancy. Epilepsia. 2009;50:206-16.
70. Wohlrab G, Leiba H, Kästle R, et al. Vigabatrin therapy in infantile spasms: solving one problem and inducing another? Epilepsia. 2009;50:2006-8.
71. Riikonen R, Carmant L, Dorofeeva M, et al. Does vigabatrin treatment for infantile spasms cause visual field defects: an international, multicentre study. Eur J Ped Neurol. 2013;17(Suppl 1):S49.
72. Izumi Y, Ishikawa M, Benz A, et al. Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia. 2004;45:1043-8.
73. Jammoul F, Wang Q, Nabbout R, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol. 2009;65:98-107.
74. Jammoul F, Degardin J, Pain D, et al. Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol Cell Neurosci. 2010;43:414-21.
75. Kinironis P, Cavalleri G, Singh R, et al. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res. 2006;70:144-52.
76. Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy in patients with epilepsy. Epilepsia. 2009;50:184-94.
77. Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009;50:195-205.
78. Dracopoulos A, Widjaja E, Raubaud C, et al. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia. 2010;51:1297-304.
79. Fong C, Osborne J, Edwards S, et al. An investigation into relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. Dev Med Child Neurol. 2013;55:862-7.
80. Glauser T, Clark P, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia. 1998;39:1324-8.
81. Zou LP, Lin Q, Qin J, et al. Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms. Topiramate Study Group. Clin Neuropharmacol. 2008;31:86-92.
82. Korinthenberg R, Schreiner A. Topiramate in children with West syndrome: a retrospective multicenter evaluation of 100 patients. J Child Neurol. 2007;22:302-6.
83. Chandra S, Bhave A, Bhargava R, et al. West syndrome: response to valproate. Front Neurol. 2012;3:166.
84. Dreifuss F, Langer D, Moline K, et al. Valproic and hepatic fatalities. II: US experience since 1984. Neurology. 1989;39:201-7.
85. Debus O, Kurlemann G. Sulthiame in the primary therapy of West syndrome: a randomised double blind placebo-controlled add-on trial on baseline pyridoxine medication. Epilepsia. 2004;45:103-8.
86. Glauser T, Pellock J. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol. 2002;17:87-96.
87. Suzuki Y, Nagai T, Ono J, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia. 1997;38:1035-8.
88. Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev. 1999;21:157-61.
89. Yanagaki S, Oguni H, Yoshii K, et al. Zonisamide for West syndrome: a comparison of clinical responses among different titration rate. Brain Dev. 2005;27:286-90.
90. Ohtsuka Y, Ogino T, Asano T, et al. Long-term follow-up of vitamin B (6)-responsive West syndrome. Pediatr Neurol. 2000;23:202-6.
91. Pietz J, Benninger C, Schafer H, et al. Treatment of infantile spasms with high dosage vitamin B6. Epilepsia. 1993;34:757-63.
92. Dreifuss F, Farwell J, Holmes G, et al. Infantile spasms: comparative trial of nitrazepam and corticotropin. Arch Neurol. 1986;43:1107-10.
93. Mikati M, El Banna D, Sinno D, et al. Response of infantile spasms to levetiracetam. Neurology. 2008;70:574-5.
94. Veggiotti P, Cieuta C, Rey E, et al. Lamotrigine in infantile spasms. Lancet. 1994;344:1375-6.
95. Kossoff E, Hedderick E, Turner Z, et al. A case-control evaluation of ketogenic diet versus ACTH for new onset infantile spasms. Epilepsia. 2008;49:1504-8.
96. Hong A, Turner Z, Hamdy R, et al. Infantile spasms treated with the ketogenic diet: prospective single-centre experience in 104 consecutive infants. Epilepsia. 2010;51:1403-7. doi: 10.1111/j.1528-1167.
97. Zou L, Wang X, Dong C, et al. Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: a 24 week, randomised, open-label, follow-up study in China. Clin Ther. 2010;32:692-700.
98. Stockler S, Plecko B, Gospe S Jr, et al. Pyridoxine dependent epilepsy and antiquitin deficiency. Clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 2011;104:48-60.
99. Riikonen R, Simell O. Tuberous sclerosis and infantile spasms. Dev Med Child Neurol. 1990;32:203-9.
100. Crino P. Evolving neurobiology of tuberous sclerosis complex. Acta Neuropathol. 2013;125:317-32.
101. Zeng L, Xu L, Gutmann D, et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63:444-53.
102. Kotulska K, Chmielewki D, Borkowska J, et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Ped Neurol. 2013;17:479-85.
103. Zhang B, McDaniel S, Rensing N, et al. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis. PLOS one. 2013;8:e57445.
104. Raffo E, Coppola A, Ono T, et al. Pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis. 2011;43:322-9.
105. Galanopoulou A, Gorter J, Cepeda C. Finding a better drug for epilepsy: the mTor pathway as an antiepileptogenic target. Epilepsia. 2012;53:1119-30.
106. Jozwiack S, Kotsulska K, Domariska Pakiela D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Pediatr Neurol. 2011;15:424-31.
107. Lagae L, Velhest H, Ceulemans B, et al. Treatment and long-term outcome in West syndrome: the clinical reality. A multicentre follow-up study. Seizure. 2010;19(3):159-64.
108. Primec Z, Stare J, Neubauer D. The risk of lower outcome in infantile spasms increases after three weeks of hypsarrhythmia duration. Epilepsia. 2006;47:2202-5.
109. Camposano SE, Major P, Halpern E, et al. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. 2008;49:1186-91.
110. O'Callaghan F, Lux A, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia. 2011;52:1359-64.
111. Riikonen R. Long-term outcome of West Syndrome: a study of adults with a history of infantile spasms. Epilepsia. 1996;37:367-72.
112. Riikonen R. Long-term outcome of patients with West syndrome. Brain Dev. 2001;23(7):683-7.
113. Stafstrom C. Infantile spasms: a critical review of emerging animal models. Epilepsy Curr. 2009;9:75-81.
114. Briggs S, Mowrey W, Hall C, et al. CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms. Epilepsia. Epub 28 Oct 2013. doi: 10.1111/epi.12424.
115. Bitton J, Sauerwein H, Weiss S, et al. A randomized controlled trial of flunarizine as add-on therapy and effect on cognitive outcome in children with infantile spasms. Epilepsia. 2012;53:1570-6.
116. Riikonen R, Jääskeläinen J, Turpeinen U. Insulin-like growth factor-1 is associated with cognitive outcome in infantile spasms. Epilepsia. 2010;51:1283-9.
117. Catania A. Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends Neurosci. 2008;31:353-60.
118. ICISS (unpublished data only) International Collaboration Infantile Spasms Study. Ongoing study. May 2007.